Novo Nordisk Introduces Lower-Cost Wegovy via Direct-to-Patient Sales Platform

In a strategic move to expand access to obesity treatment, Novo Nordisk has announced the launch of a lower-cost version of its weight-loss medication, Wegovy. The drug will now be available directly to eligible patients through NovoCare, the company’s newly established online pharmacy platform.

This initiative mirrors a similar approach recently adopted by Eli Lilly, which reduced the price of its weight-loss drug Zepbound and began offering it through its own direct-to-patient online service. By aligning Wegovy’s pricing with Zepbound’s recent cost adjustment, Novo Nordisk aims to remain competitive in the rapidly growing market for GLP-1 receptor agonists used in obesity management.

The direct-to-patient model is designed to simplify access for consumers while potentially reducing overall healthcare costs associated with intermediary distribution channels. Patients who qualify can order Wegovy directly from NovoCare, streamlining the process and ensuring timely delivery.

Novo Nordisk’s decision underscores the pharmaceutical industry’s increasing focus on addressing obesity as a chronic health condition and improving affordability for patients seeking effective treatments.

Date: March 5, 2025

Newsflash | Powered by GeneOnline AI

Related posts:

Novo Nordisk Takes on Eli Lilly in Weight Loss Drug Battle with Wegovy Price Cut Novo Nordisk Announces Price Reduction for Wegovy Weight Loss Drug Amid Growing Demand Novo Nordisk Secures Rights to Lexicon’s LX9851, Aiming to Enhance Obesity Treatments FDA Proposes Restrictions on Bulk Production of Copycat Weight Loss Drugs Amid Industry Pushback

Author

Mark Chiang